U.S. Markets closed

Coherus BioSciences, Inc. (CHRS)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
16.72-0.07 (-0.42%)
At close: 4:00PM EDT
16.72 0.00 (0.00%)
After hours: 04:42PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close16.79
Bid13.50 x 900
Ask18.70 x 900
Day's Range16.54 - 16.82
52 Week Range12.21 - 22.22
Avg. Volume663,484
Market Cap1.267B
Beta (5Y Monthly)0.99
PE Ratio (TTM)N/A
EPS (TTM)-1.06
Earnings DateNov 03, 2021 - Nov 08, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est25.71
  • GlobeNewswire

    Coherus BioSciences Mourns the Passing of Board Member Alan C. Mendelson

    REDWOOD CITY, Calif., Oct. 11, 2021 (GLOBE NEWSWIRE) -- It is with profound sadness that Coherus BioSciences, Inc. (Nasdaq: CHRS) announces the unexpected passing of board member Alan C. Mendelson. He had been a director of the Company since January 2021 and had previously served as external legal counsel since its founding in 2010. “Alan was truly a titan of the biotech industry, without peer in his discipline, and this is such a tremendous loss on so many levels for so many people,” said Denny

  • Benzinga

    Coherus' Udenyca Body Injector At par With Pre-filled syringe

    Coherus BioSciences Inc (NASDAQ: CHRS) announced results from a bioequivalence study of Udenyca (pegfilgrastim-cbqv) administered via a proprietary on-body injector (OBI) device compared to the currently marketed Udenyca pre-filled syringe (PFS). The study met all PK bioequivalence primary endpoints and the key secondary pharmacodynamic endpoint of ANC (absolute neutrophil count). No new safety signals were observed. The study enrolled 189 subjects randomized 1:1 to receive one of two treatment

  • GlobeNewswire

    Coherus Announces Positive Results of UDENYCA® On-Body Injector Clinical Trial

    - UDENYCA® On-Body Injector (OBI) Achieved Both Pharmacokinetic and Pharmacodynamic Bioequivalence in Randomized Clinical Trial - Coherus plans to seek U.S. marketing authorization for the UDENYCA® OBI in 2022 REDWOOD CITY, Calif., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“the Company”; Nasdaq: CHRS) today announced positive results from a randomized, open-label, crossover study assessing the pharmacokinetic (PK) and pharmacodynamic (PD) bioequivalence of UDENYCA® (pegfilgras